Recurrent cervical carcinoma after radical hysterectomy and pelvic lymph node dissection: a study of 32 cases

Purpose of investigation: To investigate the characteristics of patients with recurrent cervical carcinoma after radical hysterectomy and pelvic lymph node dissection (RHND), and to evaluate the effect of clinical and surgical pathologic factors on the outcome of these patients. Methods: Data from the files of 32 patients with recurrent cervical carcinoma after RHND managed at the Soroka Medical Center from 1962 through 2005 were analyzed. Results: These 32 patients represent a recurrence rate of 25.4%. The median recurrence-free interval was 19.3 (range, 1- 106) months. The prevailing signs and symptoms were obstructive nephropathy, sacral pain and bowel obstruction. Sixteen (50%) patients had loco-regional recurrence alone, 12 (27.5%) loco-regional plus distant recurrence, and four (12.5%) distant recurrence alone. Treatment modalities included radiotherapy, chemotherapy and various surgical procedures. The 5-year survival rate was 35%, with 22 (68.7%) of the patients dead of disease at the end of follow-up. Univariate analysis demonstrated a significant worsening in survival with each of the following factors: loco-regional plus distant recurrence (p = 0.010), positive pelvic lymph nodes (p = 0.010), tumor size 2 >= 3 cm (p = 0.013), positive lymph vascular space involvement (p = 0.017) and RHND without bilateral salpingo-oophorectomy (p = 0.042). In a multivariate analysis, extent of recurrent disease (locoregional alone versus loco-regional plus distant recurrence) and pelvic lymph node status (negative vs positive) at RHND were the only significant predictors of survival. Uremia was the most common cause of death. Conclusions: Recurrent cervical carcinoma after RHND is a grave disease with unfavorable prognosis. In both univariate and multivariate analyses, extent of recurrent disease and pelvic lymph node status at RHND were significant predictors of survival.

Cervical carcinoma; Radical hysterectomy; Recurrence; Prognostic factors; Survival

[1] Eralp Y., Saip P., Sakar B., Kucucuk S., Aydiner A., Dincer M. et al.: “Prognostic factors and survival in patients with metastatic or recurrent carcinoma of the uterine cervix”. Int. J. Gynecol. Cancer, 2003, 13, 497.

[2] Gebbia V., Caruso M., Testa A., Mauceri G., Borsellino N., Chiarenza M. et al.: “Vinorelbine and cisplatin for the treatment of recurrent and/or metastatic carcinoma of the uterine cervix”. Oncology, 2002, 63, 31.

[3] Hockel M.: “Surgical treatment of locally advanced and recurrent cervical carcinoma: overview on current standard and new developments”. Onkologie, 2003, 26, 452.

[4] Muggia F.M., Blessing J.A., Method M., Miller D.S., Johnson G.A., Lee R.B. et al.: “Evaluation of vinorelbine in persistent or recurrent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study”. Gynecol. Oncol., 2004, 92, 639.

[5] Wang C-J., Lai C-H., Huang H-J., Hong J-H., Chou H-H., Huang K-G. et al.: “Recurrent cervical carcinoma after primary radical surgery”. Am. J. Obstet. Gynecol., 1999, 181, 518.

[6] Samlal R.A.K., van der Velden J., van Eerden T., Schilthuis M.S., Gonzalez Gonzalez D., Lammes F.B.: “Recurrent cervical carcinoma after radical hysterectomy: an analysis of clinical aspects and prognosis”. Int. J. Gynecol. Cancer, 1998, 8, 78.

[7] Duyn A., van Eijkeren M., Kenter G., Zwinderman K., Ansink A.: “Recurrent cervical cancer: detection and prognosis”. Acta Obstet. Gynecol. Scand., 2002, 81, 759.

[8] Tinga D.J., Bouma J., Boonstra H., Aalders J.G.: “Symptomatology, localization and treatment of recurrent cervical carcinoma”. Int. J. Gynecol. Cancer, 1992, 2, 179.

[9] Eralp Y., Saip P., Sakar B., Tas F., Aydiner A., Topuz E.: “Efficacy of cisplatin and cyclophosphamide combination for recurrent and metastatic carcinoma of the uterine cervix”. Eur. J. Gynaecol. Oncol., 2003, 24, 323.

[10] Piura B., Rabinovich A., Friger M.: “Number and distribution of pelvic lymph nodes and effect of surgical pathologic factors on pelvic lymph node status in patients with early-stage cervical carcinoma treated with radical hysterectomy and pelvic lymph node dissection”. Eur. J. Gynaecol. Oncol., 2006, 27, 463.

[11] Piura B., Rabinovich A., Friger M.: “Surgical pathologic factors in patients with early-stage cervical carcinoma treated with radical hysterectomy and pelvic lymph node dissection: association with administration of adjuvant radiotherapy and effect on survival”. Eur. J. Gynaecol. Oncol., 2006, 27, 573.

[12] Piver M.S., Rutledge F.N., Smith P.J.: “Five classes of extended hysterectomy for women with cervical cancer”. Obstet. Gynecol., 1974, 44, 265.

[13] Shepherd J.H.: “Revised FIGO staging for gynaecological cancer”. Br. J. Obstet. Gynaecol., 1989, 96, 889.

[14] Swinscow T.D.V.: “Statistics at Square One”. Tavistock Square, London, British Medical Association, 1983.

[15] Kaplan E.L., Meier P.: “Non-parametric estimation from incomplete observations”. J. Am. Stat. Assoc., 1958, 53, 457.

[16] Peto R., Pike M.C., Armitage P., Breslow N.E., Cox D.R., Howard S.V. et al.: “Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples”. Br. J. Cancer, 1977, 35, 1.

[17] Cox D.R.: “Regression models and life tables”. J. Roy. Stat. Soc., 1972, 34B, 187.

[18] Grisaru D.A., Covens A., Franssen E., Chapman W., Shaw P., Colgan T. et al.: “Histopathologic score predicts recurrence free survival after radical surgery in patients with stage IA2 – IB1-2 cervical carcinoma”. Cancer, 2003, 97, 1904.